Long-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib

Lung cancer is the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitutes 3-5%. Crizotinib was approved for the first-line therapy of advanced ALK-positive NSCLC patients. We present a female patient with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Barsoum, Emad Mohsen, Eldemery, Mahmoud Mohammed, Osman, Nada Osama, Ashour, May Gamal, Barsoum, Mohsen Samy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425811/
https://www.ncbi.nlm.nih.gov/pubmed/34527107
http://dx.doi.org/10.14740/jmc3743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425811/
https://www.ncbi.nlm.nih.gov/pubmed/34527107
http://dx.doi.org/10.14740/jmc3743

Ejemplares similares